Prostate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

October 07 04:16 2023
Prostate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Prostate Cancer Pipeline Report

  • DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer treatment.
  • The leading companies working in the Prostate Cancer Market include Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed,  Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and othes.
  • Promising Prostate Cancer Pipeline Therapies in the various stages of development include Capivasertib, Enzalutamide, Abiraterone, digoxin, rosuvastatin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection and others.
  • August 2023: Bracco Diagnostics Inc. announced a study of Early Phase 1 clinical trials for BR55. The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging. This will be compared with histopathology analysis (location based on expression of VEGFR2 in tissue specimens determined by immuno-histochemistry, IHC).
  • October 2023: Astellas Pharma Global Development Inc. announced a study of Phase 2 clinical trials for enzalutamide, abiraterone acetate and prednisone. The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.

 

Request a sample and discover the recent advances in Prostate Cancer Treatment Drugs @ Prostate Cancer Pipeline Report

 

In the Prostate Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with Prostate Cancer in their lifetime.

 

Find out more about Prostate Cancer Therapeutics Assessment @ Prostate Cancer Preclinical and Discovery Stage Products

 

Prostate Cancer Emerging Drugs Profile

  • Pembrolizumab: Merck & Co
  • Talazoparib: Pfizer
  • ODM-208: Orion
  • ZEN 3694: Zenith Epigenetics
  • EPI-7386: ESSA Pharma

 

Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the Prostate Cancer therapies. The Prostate Cancer companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

 

Learn more about the emerging Prostate Cancer Pipeline Therapies @ Prostate Cancer Clinical Trials Assessment

 

Scope of the Prostate Cancer Pipeline Report

  • Coverage- Global
  • Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed,  Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and othes.
  • Prostate Cancer Pipeline Therapies- Capivasertib, Enzalutamide, Abiraterone, digoxin, rosuvastatin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection and others.

 

Dive deep into rich insights for new drugs for Prostate Cancer Treatment, Visit @ Prostate Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Prostate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Pembrolizumab: Merck & Co
  8. Drug profiles in the detailed report….
  9. Mid Stage Products (Phase II)
  10. ODM-208: Orion Pharma
  11. Drug profiles in the detailed report….
  12. Early Stage Products (Phase I)
  13. EPI 7386: ESSA Pharma
  14. Drug profiles in the detailed report….
  15. Preclinical and Discovery Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…
  18. Inactive Products
  19. Prostate Cancer Key Companies
  20. Prostate Cancer Key Products
  21. Prostate Cancer- Unmet Needs
  22. Prostate Cancer- Market Drivers and Barriers
  23. Prostate Cancer- Future Perspectives and Conclusion
  24. Prostate Cancer Analyst Views
  25. Prostate Cancer Key Companies
  26. Appendix

 

For further information on the Prostate Cancer Pipeline therapeutics, reach out to Prostate Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking